Roche Canada Concludes Perjeta Price Negotiations With Canadian Pharmaceutical Alliance

11:37 PM EDT, 08/18/2026 (MT Newswires) -- Roche's (RO.SW) Canadian arm wrapped up price negotiations with the pan-Canadian Pharmaceutical Alliance for its Perjeta medicine as a neoadjuvant treatment of aggressive early-stage breast cancer, according to a Tuesday release. The negotiations began in February after Canada's Drug Agency gave a positive recommendation to Perjeta plus trastuzumab and chemotherapy as a neoadjuvant treatment of patients with human epidermal growth factor receptor 2-positive, locally advanced, inflammatory, or early-stage breast cancer. The Swiss-listed healthcare company is cooperating with provincial and territorial authorities on reimbursement decisions that will enable access to Perjeta through public drug plans.